ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PROK ProKidney Corp.

Closed 03-20 16:00:00 EDT

1.93

-0.02

-1.03%

盘后1.93

+0.000.00%

19:44 EDT

High2.01	Low1.92	Vol690.64K
Open1.98	D1 Closing1.95	Amplitude4.62%
Mkt Cap582.70M	Tradable Cap534.28M	Total Shares301.92M
T/O1.35M	T/O Rate0.25%	Tradable Shares276.83M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PROK","market":"US","secType":"STK","nameCN":"ProKidney Corp.","latestPrice":1.93,"timestamp":1774036800000,"preClose":1.95,"halted":0,"volume":690641,"hourTrading":{"tag":"盘后","latestPrice":1.93,"preClose":1.93,"latestTime":"19:44 EDT","volume":17169,"amount":33135.1699,"timestamp":1774050290269,"change":0,"changeRate":0,"amplitude":0.006425},"delay":0,"changeRate":-0.010256410256410265,"floatShares":276830796,"shares":301916100,"eps":-0.52,"marketStatus":"Closed","change":-0.02,"latestTime":"03-20 16:00:00 EDT","open":1.98,"high":2.01,"low":1.92,"amount":1351760.2741985999,"amplitude":0.046154,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.52,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1774252800000},"marketStatusCode":5,"adr":0,"listingDate":1625025600000,"exchange":"NASDAQ","adjPreClose":1.95,"preHourTrading":{"tag":"盘前","latestPrice":1.95,"preClose":1.95,"latestTime":"08:00 EDT","volume":2495,"amount":4865.4101789999995,"timestamp":1774008000940,"change":0,"changeRate":0,"amplitude":0.005128},"postHourTrading":{"tag":"盘后","latestPrice":1.93,"preClose":1.93,"latestTime":"19:44 EDT","volume":17169,"amount":33135.1699,"timestamp":1774050290269,"change":0,"changeRate":0,"amplitude":0.006425},"volumeRatio":0.960165,"impliedVol":0.2194,"impliedVolPercentile":0.008},"requestUrl":"/m/hq/s/PROK/wiki","defaultTab":"wiki","newsList":[{"id":"2620077192","title":"Trade Policy Risks: How Evolving U.S. Tariffs and Export Rules Threaten ProKidney Corp.’s Supply Chain and Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2620077192","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620077192?lang=en_us&edition=fundamental","pubTime":"2026-03-20 14:01","pubTimestamp":1773986467,"startTime":"0","endTime":"0","summary":"Prokidney Corp. (PROK) has disclosed a new risk, in the Regulation category. ProKidney Corp. faces heightened uncertainty as evolving U.S. tariff a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/trade-policy-risks-how-evolving-u-s-tariffs-and-export-rules-threaten-prokidney-corp-s-supply-chain-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/trade-policy-risks-how-evolving-u-s-tariffs-and-export-rules-threaten-prokidney-corp-s-supply-chain-and-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2620847226","title":"Analysts Offer Insights on Healthcare Companies: ProKidney (PROK), Molecular Partners (MOLN) and Bristol-Myers Squibb (BMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620847226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620847226?lang=en_us&edition=fundamental","pubTime":"2026-03-19 21:20","pubTimestamp":1773926411,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ProKidney (PROK), Molecular Partners (MOLN) and Br...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-prokidney-prok-molecular-partners-moln-and-bristol-myers-squibb-bmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-prokidney-prok-molecular-partners-moln-and-bristol-myers-squibb-bmy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LU0225771236.USD","LU1430594728.SGD","IE00B2B36J28.USD","XBI","LU0267386448.USD","IE00BFXG1179.USD","XLV","LU1571399168.USD","LU1670711040.USD","BMY","LU1032466523.USD","LU1883839398.USD","IE00BSNM7G36.USD","IE0009355771.USD","LU2242652126.USD","BK4007","BK4532","LU1093756325.SGD","LU1670710588.SGD","LU1670710661.SGD","LU0306807586.USD","IE00BJJMRZ35.SGD","LU0096364046.USD","BK4539","LU0868494617.USD","LU1868836591.USD","LU2360032135.SGD","LU0225284248.USD","LU1989771016.USD","LU0114720955.EUR","LU0029874061.USD","BK4559","LABU","LU2125154935.USD","MOLN","HCSG","LU0237698245.USD","LU0882574055.USD","LU1868837136.USD","BK4588","BK4581","LU1670711123.USD","LU2125154778.USD","PROK","LU0306806265.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU1868837300.USD"],"gpt_icon":0},{"id":"2620244054","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvinas Holding Company (ARVN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620244054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620244054?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:17","pubTimestamp":1773919037,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ProKidney (PROK), HeartFlow, Inc. (HTFL) and Arvin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-prokidney-prok-heartflow-inc-htfl-and-arvinas-holding-company-arvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-prokidney-prok-heartflow-inc-htfl-and-arvinas-holding-company-arvn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","BK4581","BK4007","HTFL","XBI","ARVN","BK4588","LU0029874061.USD","BK4137","HCSG","PROK","XLV","BK4585","LABU","BK4167","BK4139"],"gpt_icon":0},{"id":"2620605262","title":"Prokidney Corp reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2620605262","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620605262?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:18","pubTimestamp":1773865104,"startTime":"0","endTime":"0","summary":"Prokidney Corp reports results for the quarter ended December 31 - Earnings SummaryProkidney Corp PROK.OQ reported a quarterly adjusted loss of 14 cents per share for the quarter ended December 31, hi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nL8N4062IQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2620751264","title":"ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2620751264","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620751264?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:06","pubTimestamp":1773864374,"startTime":"0","endTime":"0","summary":"ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.14) per share which missed the analyst consensus estimate of $(0.11) by 23.89 percent. This is a 12.5 percent increase over losses of $(0.16) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51339579/prokidney-q4-eps-0-14-misses-0-11-estimate-sales-225-000k-beat-83-333k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2620262986","title":"ProKidney reports Q4 EPS (52c), consensus (15c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620262986","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620262986?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:05","pubTimestamp":1773864315,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $893,000, consensus $600,000. “2025 was a pivotal year for ProKidney (PROK), highlighted by positive Phase 2 REGEN-007 study res...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/prokidney-reports-q4-eps-52c-consensus-15c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/prokidney-reports-q4-eps-52c-consensus-15c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2620264977","title":"ProKidney FY2025 revenue rises more than 10x to USD 0.89 million as net loss before noncontrolling interest narrows 7.18% to USD 151.61 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264977","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264977?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:00","pubTimestamp":1773864030,"startTime":"0","endTime":"0","summary":"ProKidney FY2025 revenue rises more than 10x to USD 0.89 million as net loss before noncontrolling interest narrows 7.18% to USD 151.61 million. ProKidney published a full-year earnings press release reporting FY 2025 revenue of USD 0.89 million. FY 2025 R&D expense fell 10.6% to USD 114.12 million, driven mainly by lower clinical study costs from trials that were completed or terminated. FY 2025 G&A expense declined 7.7% to USD 51.78 million, mainly due to lower impairment charges and equity-based compensation, partly offset by higher professional fees tied to domestication of foreign subsidiaries to the U.S. and other initiatives. FY 2025 net loss before noncontrolling interest narrowed 7.2% to USD 151.61 million. ProKidney ended FY 2025 with USD 270 million in cash, cash equivalents and marketable securities and said this should fund operations into mid-2027, while it targets completing enrollment for the Phase 3 PROACT 1 accelerated approval efficacy analysis in mid-2026 and report","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260318:nNDL6V7V6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","LU2210150020.SGD","LU2095319765.USD","BK4139","BK4585","SG9999014013.SGD","NDAQ","BK4588","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","BK4112","PROK","IE00BN0W2V16.EUR","LU0314104364.USD","LU2210149790.SGD","SG9999014021.USD","IE00BN0W2T93.GBP","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2620264115","title":"Press Release: ProKidney Reports Full Year 2025 Financial Results and Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264115","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264115?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:00","pubTimestamp":1773864000,"startTime":"0","endTime":"0","summary":"-- On track to complete enrollment for the Phase 3 PROACT 1 accelerated. approval analysis of rilparencel in mid-2026; anticipate pivotal topline. -- In a July 2025 Type B meeting, aligned with FDA on the accelerated. approval pathway for rilparencel using eGFR slope as the surrogate. -- Presented positive results from the Phase 2 REGEN-007 study of. rilparencel as a late-breaking clinical trial at ASN Kidney Week 2025. -- Ended 2025 with $270.0 million in cash and cash equivalents and. WINSTON-SALEM, N.C., March 18, 2026  -- ProKidney Corp.  , a leading late clinical-stage cell therapy company focused on chronic kidney disease , today reported financial results for the full year ended December 31, 2025, and provided business highlights.positioning the Company for a pivotal topline readout in Q2 2027 using. rilparencel. ProKidney continues to maintain its ongoing dialogue with. Journal of the American Society of Nephrology .","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK4232","R","PROK","BK4139"],"gpt_icon":0},{"id":"2618949164","title":"Prokidney Corp  expected to post a loss of 12 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618949164","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618949164?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:04","pubTimestamp":1773227045,"startTime":"0","endTime":"0","summary":"Prokidney Corp  expected to post a loss of12cents a share - Earnings Preview Prokidney Corp PROK.OQ PROK.O is expected to  show a rise in quarterly revenue when it reports  results on March 13 (estima","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nL8N3ZZ15U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2610817669","title":"U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart","url":"https://stock-news.laohu8.com/highlight/detail?id=2610817669","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610817669?lang=en_us&edition=fundamental","pubTime":"2026-02-11 16:12","pubTimestamp":1770797522,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, WalmartFeb 11 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Coca-Cola, Rapid7","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nL4N3Z70HQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SAIA","CAH","WMB","WMT","MEDP","LU1201861165.SGD","ALL","DD","EVMN","PROK","LU0320765646.SGD","WCC","RPD","LU1621767737.EUR","LU2108987350.USD","ACM","GILD","LU1221951046.USD","DGX","DDOG","LU0238689110.USD","LSCC","NET","COTY","KO","NKTR","LU0154245756.USD","LU1670710588.SGD","FISV","LU0738911758.USD","PANW","EW","LYFT","HAS","INCY","PRCH","FTV","UPST","MAT","AEIS","BLKB","KVYO","ECL","RDN","HNGE","MAS","BL","MAR","ICHR"],"gpt_icon":0},{"id":"2610600452","title":"ProKidney Corp : Jefferies Assumes Coverage With Buy Rating; Target Price $4.5 VS $6","url":"https://stock-news.laohu8.com/highlight/detail?id=2610600452","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610600452?lang=en_us&edition=fundamental","pubTime":"2026-02-11 13:52","pubTimestamp":1770789145,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260211:nFWN3Z7010:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2608052890","title":"BRIEF-Prokidney Corp - Topline Data Readout Of Surrogate Endpoint Expected Q2 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2608052890","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608052890?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:23","pubTimestamp":1770067388,"startTime":"0","endTime":"0","summary":"BRIEF-Prokidney Corp - Topline Data Readout Of Surrogate Endpoint Expected Q2 2027 Feb 2  - Prokidney Corp PROK.O:PROKIDNEY CORP - TOPLINE DATA READOUT OF SURROGATE ENDPOINT EXPECTED Q2 2027 - SEC FILINGPROKIDNEY CORP - TOPLINE DATA READOUT OF SURROGATE ENDPOINT EXPECTED IN H2 2029 - SEC FILINGPROKIDNEY CORP - UPDATES PHASE 3 STUDY ENROLLMENT TO 470 SUBJECTS - SEC FILINGFurther company coverage: PROK.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0ZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2608890324","title":"ProKidney Corp - Topline Data Readout of Surrogate Endpoint Expected Q2 2027 - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608890324","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608890324?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:06","pubTimestamp":1770066418,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0ZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2608562890","title":"ProKidney Corp - Updates Phase 3 Study Enrollment to 470 Subjects - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2608562890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608562890?lang=en_us&edition=fundamental","pubTime":"2026-02-03 05:06","pubTimestamp":1770066418,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nFWN3YY0ZG:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2601036266","title":"3 Penny Stocks With Market Caps Under $700M","url":"https://stock-news.laohu8.com/highlight/detail?id=2601036266","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601036266?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:05","pubTimestamp":1767870318,"startTime":"0","endTime":"0","summary":"Major U.S. stock indexes have recently pulled back after setting fresh all-time highs, reflecting a complex economic landscape influenced by geopolitical events and fluctuating oil prices. In this climate, investors often seek opportunities in lesser-known areas of the market where potential growth can be found. Penny stocks, despite their somewhat outdated name, represent such an opportunity by offering affordability and potential for growth when backed by strong financials.","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/3-penny-stocks-with-market-caps-under-700m","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-prok/prokidney/news/3-penny-stocks-with-market-caps-under-700m","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4023","BK4173","MAPS","BK4180","PROK","BK4139","WDH","BK4007","EGY","BK4213","BK4509","BK4551","LCUT","NMRA","LU1046422090.SGD","BK4505","TUYA","BK4526","BK4531","BK4579","BK4209","LU0049112450.USD","BK7023","BABB","CINT","DDL","BK4113","LU1235295612.USD","BK4134","BK4166","BK4539","LX","BK4121","EGY.AU","NAUT"],"gpt_icon":0},{"id":"2591984893","title":"HC Wainwright Initiates Coverage on ProKidney With Buy Rating, $12 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2591984893","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591984893?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:38","pubTimestamp":1765888731,"startTime":"0","endTime":"0","summary":"ProKidney (PROK) has an average rating of overweight and mean price target of $6.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2591981891","title":"ProKidney Initiated at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2591981891","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591981891?lang=en_us&edition=fundamental","pubTime":"2025-12-16 20:13","pubTimestamp":1765887180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PROK/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 16, 2025 07:13 ET (12:13 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PROK"],"gpt_icon":0},{"id":"2591398509","title":"ProKidney Corp. : H.c. Wainwright Initiates Coverage With Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2591398509","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2591398509?lang=en_us&edition=fundamental","pubTime":"2025-12-16 19:09","pubTimestamp":1765883370,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251216:nAZN4RFW8B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2583681026","title":"ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583681026","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583681026?lang=en_us&edition=fundamental","pubTime":"2025-11-15 05:09","pubTimestamp":1763154590,"startTime":"0","endTime":"0","summary":"Brian JG Pereira, Director of ProKidney Corp., has reported a disposal of common shares of ProKidney Corp. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prokidney Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 14, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1Wrsx1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"ProKidney Corp. Director Brian JG Pereira Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139"],"gpt_icon":0},{"id":"2582383803","title":"ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383803","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383803?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:36","pubTimestamp":1762810564,"startTime":"0","endTime":"0","summary":"ProKidney (NASDAQ:PROK) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.14) by 13.04 percent. This is a 14.29 percent increase over losses of $(0.14) per share from the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48767698/prokidney-q3-eps-0-12-beats-0-14-estimate-sales-217-000k-beat-44-250k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PROK","BK4139","QID","MNQmain","NQmain",".IXIC","NVIW.SI","PSQ","TQQQ","QLD","USJW.SI","TSYW.SI","USAW.SI","SQQQ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.prokidney.com","stockEarnings":[{"period":"1week","weight":-0.1295},{"period":"1month","weight":-0.0347},{"period":"3month","weight":-0.1772},{"period":"6month","weight":-0.2724},{"period":"1year","weight":0.9677},{"period":"ytd","weight":-0.1295}],"compareEarnings":[{"period":"1week","weight":-0.0094},{"period":"1month","weight":-0.0338},{"period":"3month","weight":-0.0305},{"period":"6month","weight":-0.0059},{"period":"1year","weight":0.1634},{"period":"ytd","weight":-0.0324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":0.022112},{"month":2,"riseRate":0.8,"avgChangeRate":0.049183},{"month":3,"riseRate":0.4,"avgChangeRate":-0.08812},{"month":4,"riseRate":0.5,"avgChangeRate":0.025444},{"month":5,"riseRate":0.75,"avgChangeRate":0.19736},{"month":6,"riseRate":0.25,"avgChangeRate":-0.136783},{"month":7,"riseRate":0.4,"avgChangeRate":0.747675},{"month":8,"riseRate":0.2,"avgChangeRate":-0.09753},{"month":9,"riseRate":0.4,"avgChangeRate":-0.139421},{"month":10,"riseRate":0.6,"avgChangeRate":-0.082174},{"month":11,"riseRate":0.4,"avgChangeRate":-0.019735},{"month":12,"riseRate":0.6,"avgChangeRate":-0.066082}],"exchange":"NASDAQ","name":"ProKidney Corp.","nameEN":"ProKidney Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ProKidney Corp.(PROK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ProKidney Corp.,PROK,ProKidney Corp.股票,ProKidney Corp.股票老虎,ProKidney Corp.股票老虎国际,ProKidney Corp.行情,ProKidney Corp.股票行情,ProKidney Corp.股价,ProKidney Corp.股市,ProKidney Corp.股票价格,ProKidney Corp.股票交易,ProKidney Corp.股票购买,ProKidney Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ProKidney Corp.(PROK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ProKidney Corp.(PROK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}